AI, Google and DeepMind

AI-developed drug will be in trials by year-end, says Google’s Hassabis
Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big pharmaceutical partners, which are keen to lower expenses and boost efficiency of the costly drug development process.
Google-backed, AI-developed drugs are headed to trial by 2026, DeepMind CEO says
Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.
Google DeepMind CEO says 2025's the year we start popping pills AI helped invent
Nobel Prize winner Demis Hassabis thinks human trials will happen soon Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google DeepMind CEO Demis Hassabis suggested Tuesday.
Trials of drugs developed with AI could begin this year, Google DeepMind CEO says
The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.
Europe accelerates AI drug discovery as DeepMind spinoff targets trials this year
Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups race to turn algorithmic magic into actual treatments. “We’ll hopefully have
DeepMind expects clinical trials for AI-designed drugs this year
Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this year, according to its Nobel Prize-winning chief executive officer. “We’ll hopefully have some AI-designed drugs in clinical trials by the end of the year,
Google's DeepMind eyes clinical trials for AI-designed drugs in 2025 - report
Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis. "We'll hopefully have some AI-designed drugs in clinical trials by the end of the year,
Roll over, Darwin: How Google DeepMind's 'mind evolution' could enhance AI thinking
This new approach, based on natural selection, dramatically improves the reliability of large language models for practical ...
Why AI Creatives Are Touting Google’s Veo 2 as Best Video Generation Model
AI creatives with access to Google’s Veo 2 text-to-video tool say it’s another “leap forward” for video generation Veo 2 ...
Google rushed to sell AI tools to Israel’s military after Hamas attack
The company fulfilled requests from Israel’s military for more access to AI tools as it sought to compete with Amazon, ...
DeepMind’s new inference-time scaling technique improves planning accuracy in LLMs
With "Mind Evolution" LLMs can use search and genetic algorithms to generate and combine different solutions and find the optimal one.
The Prompt: Inside Google's AI Innovation Engine
The order, signed in October 2023, required companies building powerful AI systems to share their safety test results with the federal government and come up with ways to limit their models’ biases ...
BI Davos Diary: Tech leaders worry the AI hype is missing the big picture
Business Insider's diary takes you behind the scenes on day three of the World Economic Forum in Davos.
CNET on MSN20h
Samsung Galaxy S25 Ultra Hands On: AI Everywhere, Plus a Bigger Screen
Samsung's Galaxy S25 phones are all about AI. But the Ultra also gets a larger screen and a slightly refreshed look with ...
From Musk to Nadella: Trump's $500 billion AI project stirs drama among the biggest names in tech
Some of the biggest names in technology have clashed after President Donald Trump unveiled his $500 billion private AI investment project.